<DOC>
	<DOCNO>NCT01448499</DOCNO>
	<brief_summary>Background : schizophrenia debilitate mental disorder affect 1 % general population . About 30 % patient react current drug treatment define treatment-resistant schizophrenia patient ( TRSP ) . The best studied therapeutic option population clozapine therapy . Clozapine show effective antipsychotic drug TRSP . Moreover , augmentation clozapine demonstrate effective clozapine monotherapy . Albeit Clozapine superiority TRSP , use may involve many adverse effect , life-threatening , need routine blood test . Amisulpride atypical antipsychotic drug different mechanism action clozapine , less adverse effect . No study compare directly amisulpride clozapine TRSP . Study objective : compare , first time , broad clinical effectiveness clozapine amisulpride combination TRSP . Study Design : clinical , prospective , naturalistic , randomize , comparative study simulate real-world approach clinical decision making . Methods : total 140 TRSP recruit large regional mental health center . Participants randomize two treatment group ( 70 group ) : clozapine monotherapy amisulpride monotherapy . Assessment do follow 10 20 week treatment . In case treatment failure ( insufficient clinical response severe adverse effect ) participant offer either switch clozapine treatment ( failed amisulpride treatment ) augment clozapine amisulpride ( failed clozapine monotherapy patient ) . Thereafter , participant followed-up year . Assessment make use clinician rat scale self-completed questionnaire , rating broad phenomenology schizophrenia ( psychosis , mood , anxiety , obsessive-compulsive , cognitive quality life ) drug-related adverse effect ( objective subjective ) . Analysis : comparison effectiveness three treatment group : amisulpride , clozapine combination , various dimension TRSP .</brief_summary>
	<brief_title>Clozapine Versus Amisulpride Treatment-resistant Schizophrenia Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>1 . Confirmed diagnosis schizophrenia accord DSMIVTR criterion 2 . Treatmentresistant schizophrenia , define : document treatment failure ( insufficient clinical response severe adverse effect ) two antipsychotic ( one atypical ) adequate duration 6 week sufficient dose least 600 mg/day chlorpromazine equivalent 3 . Age 1865 year 4 . Basal PANSS &gt; 75 5 . CGIS &gt; 3 6 . Persistent positive psychotic symptom , rating score moderate bad least two four positive symptom item ( delusion , conceptual disorganization , hallucinatory behavior , suspiciousness/persecution ) Positive Negative Syndrome Scale ( PANSS ) . 7 . Competent willing provide write , inform consent 1 . Patients concomitant treatment lithium , anticonvulsant , antidepressant 2 . Patients underlie severe medical illness , cardiovascular disease , cerebrovascular disease , bone marrow suppression epilepsy 3 . A previous trial clozapine amisulpride 4 . Any known contraindication treatment clozapine amisulpride 5 . Any woman pregnant planning pregnancy , woman child bear potential unless use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>clozapine</keyword>
	<keyword>amisulpride</keyword>
	<keyword>combination</keyword>
	<keyword>treatment resistant</keyword>
</DOC>